Nevanac Evrópusambandið - íslenska - EMA (European Medicines Agency)

nevanac

novartis europharm limited - nepafenak - pain, postoperative; ophthalmologic surgical procedures - augnlækningar - nevanac is indicated for: , prevention and treatment of postoperative pain and inflammation associated with cataract surgery;, reduction in the risk of postoperative macular oedema associated with cataract surgery in diabetic patients.

Pro-Epanutin Stungulyf, lausn/innrennslisþykkni, lausn 50 mg FE/ml Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

pro-epanutin stungulyf, lausn/innrennslisþykkni, lausn 50 mg fe/ml

pfizer aps - fosphenytoinum dínatríum - stungulyf, lausn/innrennslisþykkni, lausn - 50 mg fe/ml

Flutiform (Affilia) Innúðalyf, dreifa 125 míkróg/5 míkróg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

flutiform (affilia) innúðalyf, dreifa 125 míkróg/5 míkróg

mundipharma a/s - fluticasonum própíónat; formoterolum fúmarat - innúðalyf, dreifa - 125 míkróg/5 míkróg

Flutiform (Affilia) Innúðalyf, dreifa 250 míkróg/10 míkróg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

flutiform (affilia) innúðalyf, dreifa 250 míkróg/10 míkróg

mundipharma a/s - fluticasonum própíónat; formoterolum fúmarat - innúðalyf, dreifa - 250 míkróg/10 míkróg

Flutiform (Affilia) Innúðalyf, dreifa 50 míkróg/5 míkróg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

flutiform (affilia) innúðalyf, dreifa 50 míkróg/5 míkróg

mundipharma a/s - fluticasonum própíónat; formoterolum fúmarat - innúðalyf, dreifa - 50 míkróg/5 míkróg

Suiseng Diff/A Evrópusambandið - íslenska - EMA (European Medicines Agency)

suiseng diff/a

laboratorios hipra, s.a. - clostridioides difficile toxoid a, clostridioides difficile toxoid b, clostridium perfringens, type a, alpha toxoid - immunologicals for suidae, inactivated bacterial vaccines for pigs, clostridium - svín - for the passive immunisation of neonatal piglets by means of the active immunisation of breeding sows and gilts:- to prevent mortality and reduce clinical signs and macroscopic lesions caused by clostridioides difficile toxins a and b. - to reduce clinical signs and macroscopic lesions caused by clostridium perfringens type a, alpha toxin.

Cisordinol Filmuhúðuð tafla 10 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

cisordinol filmuhúðuð tafla 10 mg

h. lundbeck a/s* - zuclopenthixolum díhýdróklóríð - filmuhúðuð tafla - 10 mg

Cisordinol Filmuhúðuð tafla 2 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

cisordinol filmuhúðuð tafla 2 mg

h. lundbeck a/s* - zuclopenthixolum díhýdróklóríð - filmuhúðuð tafla - 2 mg

Cisordinol Depot Stungulyf, lausn 200 mg/ml Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

cisordinol depot stungulyf, lausn 200 mg/ml

h. lundbeck a/s* - zuclopenthixolum decanóat - stungulyf, lausn - 200 mg/ml